Center for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Center for Chemistry and Biomedicine, Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, 6020 Innsbruck, Austria.
Int J Pharm. 2024 May 10;656:124075. doi: 10.1016/j.ijpharm.2024.124075. Epub 2024 Apr 9.
This study aims to design chemically crosslinked thiolated cyclodextrin-based hydrogels and to evaluate their mucoadhesive properties via mucosal residence time studies on porcine small intestinal mucosa and on porcine buccal mucosa.
Free thiol groups of heptakis(6-deoxy-6-thio)-β-cyclodextrin (β-CD-SH) were S-protected with 2-mercaptoethanesulfonic acid (MESNA) followed by crosslinking with citric acid. Cytotoxicity was assessed by hemolysis as well as resazurin assay. Hydrogels were characterized by their rheological and mucoadhesive properties. Ritonavir was employed as model drug for in vitro release studies from these hydrogels.
The structure of S-protected β-CD-SH was confirmed by IR and H NMR spectroscopy. Degree of thiolation was 390 ± 7 µmol/g. Hydrogels based on native β-CD showed hemolysis of 12.5 ± 2.5 % and 13.6 ± 2.7 % within 1 and 3 h, whereas hemolysis of just 3.5 ± 2.8 % and 3.9 ± 3.0 % was observed for the S-protected thiolated CD hydrogels, respectively. Both native and S-protected thiolated hydrogels showed minor cytotoxicity on Caco-2 cells. Rheological investigations of S-protected thiolated β-CD-based hydrogel (16.2 % m/v) showed an up to 13-fold increase in viscosity in contrast to the corresponding native β-CD-based hydrogel. Mucosal residence time studies showed that thiolated β-CD-based hydrogel is removed to a 16.6- and 2.4-fold lower extent from porcine small intestinal mucosa and porcine buccal mucosa in comparision to the native β-CD-based hydrogel, respectively. Furthermore, a sustained release of ritonavir from S-protected thiolated β-CD-based hydrogels was observed.
Because of their comparatively high mucoadhesive and release-controlling properties, S-protected thiolated β-CD-based hydrogels might be promising systems for mucosal drug delivery.
本研究旨在设计化学交联的巯基化环糊精水凝胶,并通过在猪小肠黏膜和猪颊黏膜上进行黏膜滞留时间研究来评估其黏膜黏附特性。
用 2-巯基乙磺酸(MESNA)对七(6-去氧-6-硫代)-β-环糊精(β-CD-SH)的游离巯基进行 S-保护,然后用柠檬酸进行交联。通过溶血和resazurin 测定评估细胞毒性。通过流变学和黏膜黏附特性对水凝胶进行表征。利托那韦被用作这些水凝胶体外释放研究的模型药物。
S-保护的 β-CD-SH 的结构通过 IR 和 H NMR 光谱得到证实。巯基化程度为 390±7µmol/g。基于天然 β-CD 的水凝胶在 1 和 3 小时内的溶血率分别为 12.5±2.5%和 13.6±2.7%,而 S-保护的巯基化 CD 水凝胶的溶血率分别仅为 3.5±2.8%和 3.9±3.0%。天然和 S-保护的巯基化水凝胶对 Caco-2 细胞的细胞毒性均较小。S-保护的巯基化 β-CD 水凝胶(16.2%m/v)的流变学研究表明,与相应的天然 β-CD 水凝胶相比,其粘度增加了 13 倍。黏膜滞留时间研究表明,与天然 β-CD 水凝胶相比,巯基化 β-CD 水凝胶从猪小肠黏膜和猪颊黏膜上的去除程度分别降低了 16.6 倍和 2.4 倍。此外,观察到 S-保护的巯基化 β-CD 水凝胶中利托那韦的持续释放。
由于其具有较高的黏膜黏附性和释放控制特性,S-保护的巯基化 β-CD 水凝胶可能是用于黏膜给药的有前途的系统。